Transinsight's GoPubMed with Social Networking Features for Biomedical Experts

Biomedical research happens in networks of researchers. Social networking web sites like FaceBook, LinkedIn and Xing use personal networks to establish contacts. On these sites, however, connections must be defined by the users themselves. For the first time, GoPubMed now completely and automatically extracts collaboration networks from millions of biomedical science publications. For each concept in the selected semantic background knowledge, GoPubMed's "Hot-Topic-View" shows the collaboration network between top authors in this field of research. Collaboration networks can now be experienced and visualized. GoPubMed also now allows these networks to be searched for possible experts and collaboration partners, a feature which leads to tremendous time saving when searching for appropriate experts. This feature is especially important in a specialized scientific world where it is becoming more and more vital to set up temporary teams of highly specialized experts.

"Some author names like Lee S., Smith J. and Müller C. appear over 20,000 times! We have solved the technical challenge of disambiguating the authors into single individuals with our semantic search technology, which in a way functions like the network of the brain", says Prof. Dr. Michael Schroeder, CSO and co-founder of Transinsight. If two articles share the same author, GoPubMed evaluates their similar properties. The system hereby takes into account that the author of each paper often publishes about similar research topics, with the same co-authors and in the same journals. The research topics are thereby connected to the concepts of the semantic network in the background. The more concepts two articles have in common and the shorter the semantic distance in the network is, the more likely it is that the articles were written by the same person. This approach leads to impressive accuracy. If at any point the system is not correct, it can be corrected by the users.

"GoPubMed is an essential step in significantly easing the finding of complexly networked information", according to Prof. Dr. Michael Brand, Director of the BioInnovation Center in Dresden. "The semantic approach is unparalleled worldwide, and I'm excited that such a development, which would be expected to come from Palo Alto's Stanford University in the Silicon Valley in California, today comes instead from Dresden," says Brand.

For further information, please visit:
www.GoPubMed.com

Related news articles:

About Transinsight
Founded in 2005, Transinsight is focused on software solutions for the life sciences providing products for knowledge-based technologies. The flagship product, www.gopubmed.com, a well established biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof. Transinsight works in close collaboration with the Technical University Dresden. For further information, visit www.transinsight.com.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pill for skin disease also curbs excessive drinkin…

Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promi...

Pfizer's elranatamab receives FDA and EMA filing a…

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company's Biologics License Application (BLA) ...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...